Fasting and cancer treatment in humans: A case series report by Safdie, Fernando M. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Chemotherapy can extend survival in patients diagnosed 
with a wide range of malignancies. However, side 
effects caused by toxicity to normal cells and tissues limit 
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chemotherapy dose density and intensity, which may 
compromise efficacy. For instance, the cardiotoxicity 
and nephrotoxicity associated with the widely 
prescribed anti-cancer drugs, doxorubicin and cisplatin 
respectively limit their full therapeutic potential [1, 4]. 
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Abstract: Short‐term fasting (48 hours) was shown to be effective in protecting normal cells and mice but not cancer cells
against high dose chemotherapy, termed Differential Stress Resistance (DSR), but the feasibility and effect of fasting in
cancer patients undergoing chemotherapy is unknown. Here we describe 10 cases in which patients diagnosed with a
variety of malignancies had voluntarily fasted prior to (48‐140 hours) and/or following (5‐56 hours) chemotherapy. None of
these patients, who received an average of 4 cycles of various chemotherapy drugs in combination with fasting, reported
significant  side  effects  caused  by  the  fasting  itself  other  than  hunger  and  lightheadedness.  Chemotherapy  associated
toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer
Institute (NCI). The six patients who underwent chemotherapy with or without fasting reported a reduction in fatigue,
weakness, and gastrointestinal side effects while fasting. In those patients whose cancer progression could be assessed,
fasting did not prevent the chemotherapy‐induced reduction of tumor volume or tumor markers. Although the 10 cases
presented  here  suggest  that  fasting  in  combination  with  chemotherapy  is  feasible,  safe,  and  has  the  potential  to
ameliorate  side  effects  caused  by  chemotherapies,  they  are  not  meant  to  establish  practice  guidelines  for  patients
undergoing  chemotherapy.  Only  controlled‐randomized  clinical  trials  will  determine  the  effect  of  fasting  on  clinical
outcomes including quality of life and therapeutic index. 
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protection of normal cells without compromising the 
killing of malignant cells represents a promising 
strategy to enhance cancer treatment. 
 
Calorie restriction (CR) is an effective and reproducible 
intervention for increasing life span, reducing oxidative 
damage, enhancing stress resistance and delaying/preven- 
ting aging and age-associated diseases such as cancer in 
various species, including mammals  (mice, rats, and non- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
human primates) [5-8]. Recently, a fasting-based 
intervention capable of differentially protecting normal 
and cancer cells against high-dose chemotherapy in cell 
culture and in neuroblastoma-bearing mice was reported 
[9]. In the neuroblastoma xenograft model, mice were 
allowed to consume only water for 48 hours prior to 
etoposide treatment. Whereas high dose etoposide led to 
50% lethality in ad libitum fed mice, fasting protected 
against the chemotoxicity without compromising the 
killing of neuroblastoma cells [9].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Toxicity side effect survey 
 
Fatigue ** 
0 1  2  3    4 Being extreme Fatigue 
Weakness ***  0 1  2  3  4 
4 Being Extreme Weakness 
Hair Loss  0 1  2  3  4 
4 Being Maximum Hair Loss 
36.5°C 
/97.7° 
37.0°C 
/98.6° 
37.5°C 
/99.5° 
38.0°C 
/100.4° 
38.5°C 
/101.3° 
39.0°C 
/102.2° 
39.5°C 
/103.1° 
40.0°C 
/104° 
40.5°C 
/104.9° 
41.0°C 
/105.8°  Body Temperature   
Head Aches  0 1  2  3  4 
4 Being the Worst Headache 
Gastrointestinal Side Effects 
Appetite  0 1  2  3  4 
4 Being Strong Appetite 
Nausea  0 1  2  3  4 
4 Being Unbearable Nausea 
Mild Moderate  Severe 
0  Vomiting  < 2 times/Day  3-5 times/ Day  >5 times/Day 
Mild Moderate  Severe 
0  Diarrhea  < 2 times/Day  3-5 times/ Day  >5 times/Day 
Abdominal Cramps 
0 1  2  3  4  4 Being Extreme Abdominal 
Cramps 
Mouth Sores  0 1  2  3  4 
4 Being Extremely Painful 
Dry Mouth 
0  1  2  3                  4 
4 Extreme Dryness 
CNS AND PNS Side Effects 
Short memory impairment  0 
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     4 
4 Being High Impairment 
Numbness  0 1  2  3  4 
4 Being Maximum 
Tingling  0 1  2  3  4 
4 Being Maximum 
Neuropathy-motor 
0 1  2  3  4 
4 Being = Paralysis 
* Grade: 0 no symptom, 1 to 4 from mild, moderate, severe and life threatening (requires medical assistance) 
** Fatigue: unusual tiredness which is not relieved by either a good night of sleep or rest. 
*** Weakness: lack of strength, vigor or firmness Previous human studies have shown that alternate day 
dietary restriction and short-term fasting (5 days) are 
well tolerated and safe [10-12]. In fact, children ranging 
from 6 months to 15 years of age were able to complete 
14 to 40 hours of fasting in a clinical study carried out 
at the Children’s hospital of Philadelphia [13]. 
Furthermore, alternate day calorie restriction caused 
clinical improvements and reduced markers of 
inflammation and oxidative stress in obese asthmatic 
patients [12, 14].  
 
Here, we report 10 cases of patients diagnosed with 
various types of cancer, who have voluntarily fasted 
prior to and following chemotherapy. The results 
presented here, which are based on self-assessed health 
outcomes (Table 1) and  laboratory reports,  suggest that  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fasting is safe and raise the possibility that it can reduce 
chemotherapy-associated side effects. However, only a 
randomized controlled clinical trial can establish its 
efficacy.  
 
RESULTS 
 
Ten cancer patients receiving chemotherapy, 7 females 
and 3 males with a median age of 61 years (range 44-78 
yrs), are presented in this case series report. Four suffered 
from breast cancer, two from prostate cancer, and one 
each from ovarian, uterine, non small cell carcinoma of 
the lung, and esophageal adenocarcinoma. All patients 
voluntarily fasted for a total of 48 to 140 hours prior to 
and/or 5 to 56 hours following chemotherapy 
administered by their treating oncologists (Tables 2, 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Self‐reported side‐effects after chemotherapy with or without fasting. Data
represent average of CTCAE grade from matching fasting and non‐fasting cycles (Ad Lib). 6 patients
received either chemotherapy‐alone or chemo‐fasting treatments. Self‐reported side effects from
the closest two cycles were compared one another. Statistic analysis was performed only from
matching cycles. Data presented as standard error of the mean (SEM). P value was calculated with
unpaired, two tail t test. (*, P<0.05). 
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Table 2. Additional data from patients, including scheme of chemotherapy cycles, fasting regimens 
and tumor response 
 
 Cycle 
# 
Fast 
(hours) 
Chemotherapy  Tumor Response 
Case 1  1 140  pre 
40 post 
Docetaxel 75mg/m
2 + 
Cyclophosphamide 600mg/m
2  n/a 
  4 120  pre 
24 post 
Docetaxel 75mg/m
2 + 
Cyclophosphamide 600mg/m
2  n/a 
Case 2  4 72  pre 
51 post 
Docetaxel 64.6mg/m
2 + carboplatin 485mg 
+ 5FU 2415.7 mg/m
2  --- 
  5 48  pre 
56 post 
Docetaxel 79 mg/m
2 + carboplatin 470mg 
+ 5FU 2415.7 mg/m
2  Stable disease on CT/PET 
  6 48  pre 
56 post 
Docetaxel 79 mg/m
2 + carboplatin 470mg 
+ 5FU 2415.7 mg/m
2 
Improvement on CT/PET. 
Refer to text. 
  7 48  pre 
56 post 
Docetaxel 79 mg/m
2 + carboplatin 470mg 
+ 5FU 2415.7 mg/m
2  --- 
  8 48  pre 
56 post 
Docetaxel 79 mg/m
2 + carboplatin 470mg 
+ 5FU 2415.7 mg/m
2 
Progression of Disease on 
CT/PET 
Case 3  5- 12  60-66 pre 
24 post 
Docetaxel 75 mg/m
2 
See PSA Graph 
Case 4  6 48  pre 
24 post 
Docetaxel 75mg/m
2 + carboplatin 540mg  Stable disease CT/PET refer to 
text 
Case 5  2  36 pre  Carboplatin 480 mg + Paclitaxel 280 mg 
--- 
  3-4  60 pre  Carboplatin 480 mg + Paclitaxel 280 mg  87% decline in CA 125, 
Reduction in lymph nodes on 
CT 
  5-6 60  pre 
24post 
Carboplatin 480 mg + Paclitaxel 280 mg   
Case 6  3 62  pre 
24post 
Gemcitabine 720 mg/m
2 (day1)+ 
GMZ 720 mg/m
2 Docetaxel 80 mg/m2 (Day8)  --- 
  4 62  pre 
24post 
Gemcitabine 720 mg/m
2 (day1)+ 
GMZ 720 mg/m
2 Docetaxel 80 mg/m2 (Day8)  --- 
  5-6 62  pre 
24post 
Gemcitabine 900 mg/m
2 (day1)+ 
GMZ 900 mg/m
2 Docetaxel 100 mg/m2 (Day8) 
Stable disease on PET scan, 
No new METS. 
Case 7  1 65  pre 
8 post 
Docetaxel 60 mg/m
2 
See PSA Graph 
  2-8 65  pre 
25post*^ 
Docetaxel 75 mg/m
2  See PSA Graph 
Case 8  1-4 64  pre 
24 post** 
Docetaxel 75 mg/m
2 + Cyclophosphamide 600 
mg/m
2  n/a 
Case 9  1  48 pre  Doxorubicin 110 mg + 
Cyclophosphamide 1100 mg  n/a 
  2-4 61  pre 
4 post 
Doxorubicin 110 mg + 
Cyclophosphamide 1100 mg  n/a 
Case 10  1  60 pre  Docetaxel 75 mg/m
2 + Carboplatin 400mg  n/a 
  2  48 pre  Docetaxel 75 mg/m
2 + carboplatin 400mg  n/a 
  3 40  pre 
24post 
Docetaxel 75 mg/m
2 + carboplatin 400mg 
n/a 
  4 48  pre 
24post 
Docetaxel 75 mg/m
2 + carboplatin 400mg  n/a 
  5 36  pre 
24post 
Docetaxel 75 mg/m
2 + carboplatin 400mg  n/a 
  6 20  pre 
20post 
Docetaxel 75 mg/m
2 + carboplatin 400mg  n/a 
* also utilized low glycemic diet for 24 hours prior to fast. 
** also utilized liquid diet for 24 hours after fast. 
n/a = not applicable, due to chemotherapy being administered in the adjuvant setting. 
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Case 1 
 
This is a 51-year-old Caucasian woman diagnosed with 
stage IIA breast cancer receiving adjuvant chemo-
therapy consisting of docetaxel (TAX) and cyclo-
phosphamide (CTX). She fasted prior to her first 
chemotherapy administration. The fasting regimen 
consisted of a complete caloric deprivation for 140 
hours prior and 40 hours after chemotherapy (180 hours 
total), during which she consumed only water and 
vitamins. The patient completed this prolonged fasting 
without major inconvenience and lost 7 pounds, which 
were recovered by the end of the treatment (Figure 2H). 
After the fasting-chemotherapy cycle, the patient 
experienced mild fatigue, dry mouth and hiccups 
(Figure 2I); nevertheless she was able to carry out her 
daily activities (working up to 12 hours a day). By 
contrast, in the subsequent second and third treatment, 
she  received chemotherapy accompanied by  a regular  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Additional demographical and clinical information of patients 
 
  Gender  Age  Primary Neoplasia  Stage at Diagnosis 
Case 1  Female 51 Breast IIA 
Case 2  Male 68  Esophagus  IVB 
Case 3  Male 74  Prostate  II 
Case 4  Female 61  Lung  (NSCLC)  IV 
Case 5  Female 74 Uterus IV 
Case 6  Female 44  Ovary IA 
Case 7  Male 66  Prostate  IV/DI 
Case 8  Female 51 Breast IIA 
Case 9  Female 48 Breast IIA 
Case 10  Female 78 Breast IIA 
 
 
 
 
 
 
 
 
 
diet and complained of moderate to severe fatigue, 
weakness, nausea, abdominal cramps and diarrhea 
(Figure 2I). This time the side effects forced her to 
withdraw from her regular work schedule. For the forth 
cycle, she opted to fast again, although with a different 
regimen which consisted of fasting 120 hours prior to 
and 24 hours post chemotherapy. Notably, her self-
reported side effects were lower despite the expected 
cumulative toxicity from previous cycles. Total white 
blood cell (WBC) and absolute neutrophil counts (ANC) 
were slightly better at nadir when chemotherapy was 
preceded by fasting (Figure 2A, C; Table S1). 
Furthermore, platelets level decreased by 7-19% during 
cycles 2 and 3 (ad libitum diet) but did not drop during 
the first and forthcycles (fasting), (Figure 2D). After the 
forthchemotherapy cycle combined with 144-hour fast 
her ANC, WBC, and platelet counts reached their 
highest level since the start of chemotherapy 80 days 
earlier (Figure 2A, C and D). 
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Case 2 
 
This is a 68-year-old Caucasian male diagnosed in 
February 2008 with esophageal adenocarcinoma 
metastasic to the left adrenal gland. The initial treatment 
consisted of 5-fluorouracil (5-FU) combined with 
cisplatin (CDDP) concurrent with radiation for the first 
two cycles. Throughout these first two cycles,  the patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Laboratory values of blood cell counts for case 1. (A) Neutrophils; (B) Lymphocytes; (C) White blood cells, WBC; (D) Platelets;
(E) Red blood cells, RBC (F) Hemoglobin, Hgb; (G) Hematocrit, Hct;  (H) Body weight. Filled triangle indicates day of chemotherapy; open
square indicates fasting. Normal ranges of laboratory values are indicate by dash lines; (I) Self‐reported side‐effects after chemotherapy for
case 1. Data represent the average of 2 cycles of chemo‐alone vs the average of 2 cycles of chemo‐fasting treatments. 
 
 
 
 
experienced multiple side effects including severe 
weakness, fatigue, mucositis, vomits and grade 2-3 
peripheral neuropathy (Figure 3). During the third 
cycle, 5-FU administration was interrupted due to 
severe nausea and refractory vomiting (Figure 3). In 
spite of the aggressive approach with chemotherapy and 
radiation, his disease progressed with new metastases to 
the right adrenal gland, lung nodules, left sacrum, and 
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- positron emission tomography (CT-PET) performed in 
August 2008. These prompted a change in his 
chemotherapy regimen for the fourth cycle to 
carboplatin (CBDCA) in combination with TAX and 5-
FU (96 hour infusion) (Table 2). During the fourth 
cycle, the patient incorporated a 72-hour fast prior to 
chemotherapy and continued the fast for 51 hours 
afterward, consuming only water. The rationale for the 
51 hour post-chemotherapy fasting was to cover the 
period of continuous infusion of 5-FU. The patient lost 
approximately 7 pounds, of which 4 were regained 
during the first few days after resuming ad libitum diet 
(data not shown). Although a combination of three 
chemotherapeutic agents were used during this cycle, 
self-reported side effects were consistently less severe 
compared to cycles in which calories were consumed ad 
lib (Figure 3). Prior to his fifth cycle the patient opted to  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fast again. Instead of receiving the 5-FU infusion for 96 
hours, as he did previously, the same dose of the drug 
was administered within 48 hours, and the fasting 
regimen was also modified to 48 hours prior and 56 
hours post chemotherapy delivery. Self-reported side 
effects were again less severe than those in association 
with  ad libitum diet and the restaging CT-PET scan 
indicated objective tumor response, with decreased 
standard uptake values (SUV) in the esophageal mass, 
the adrenal gland metastases, and the lung nodule. From 
the sixth to eight cycle, the patient fasted prior to and 
following chemotherapy treatments (Table 2). Fasting 
was well tolerated in all cycles and chemotherapy-
dependent side effects were reduced except for mild 
diarrhea and abdominal cramps that were developed 
during the seventh cycle (Figure 3). Ultimately, the 
patient’s disease progressed and the patient died in 
February 2009. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Self‐reported side‐effects after chemotherapy for case 2. Data represent the
average of 3 cycles of chemo‐alone vs the average of 5 cycles of chemo‐fasting treatments. 
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This is a 74-year-old Caucasian man who was 
diagnosed in July 2000 with stage II prostate adeno-
carcinoma, Gleason score 7 and baseline PSA level of 
5.8 ng/ml. He achieved an undetectable PSA nadir after 
radical prostatectomy performed in September of 2000, 
but experienced biochemical recurrence in January 2003 
when PSA rose to 1.4 ng/ml. Leuprolide acetate 
together with bicalutamide and finasteride were 
prescribed. However, administration of these drugs had 
to be suspended in April 2004  due to severe side effects  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
related to testosterone deprivation. Additional therapies 
including triptorelin pamoate, nilutamide, thalidomide, 
CTX and ketoconazole failed to control the disease. In 
2007 the patient’s PSA level reached 9 ng/ml and new 
metastases were detected on bone scan. Despite that 
TAX at 25mg/m
2 was administered on weekly basis, the 
PSA level continued to increase, reaching 40.6 ng/ml 
(data not shown).  Bevacizumab was added to the 
treatment and only then did the PSA drop significantly 
(data not shown). Throughout the cycles with 
chemotherapy the patient experienced significant side 
effects including fatigue, weakness, metallic taste, dizzi- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Laboratory values of blood cell counts for case 3. (A) Neutrophils; (B) Lymphocytes; (C) White blood cells, WBC; (D)
Platelets; (E) Red blood cells, RBC (F) Hemoglobin, Hgb; (G) Hematocrit, Hct; (H) Prostate specific antigen (PSA) level. The patient was
enrolled in abiraterone acetate (CYP17 inhibitor) trial for 90  days indicated by vertical dash lines. The patient also received G‐CSF
(Neulasta)  on  the  day  of  chemotherapy  except  during  the  treatment  with  abiraterone  acetate.  Filled  triangle  indicates  day  of
chemotherapy; open square indicates fasting, arrow indicates testosterone application (cream 1%). Normal ranges of laboratory values
are indicated by horizontal dash lines; (I) Self‐reported side‐effects after chemotherapy for case 3. Data represent the average of 5 cycles
of chemo‐alone vs the average of 7 cycles of chemo‐fasting treatments. 
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peripheral neuropathy (Figure 4I). After discontinuing 
the chemotherapy, his PSA rose rapidly. TAX was 
resumed at 75mg/m
2  every 21 days, and was 
complemented with granulocytic colony stimulating 
factor (G-CSF). Once again the patient suffered 
significant side effects (Figure 4I). In June 2008, 
chemotherapy was halted. The patient was enrolled in a 
phase III clinical trial with abiraterone acetate, a drug that 
can selectively block CYP17, a microsomal enzyme that
 
catalyzes a series of reactions critical to nongonadal 
androgen
 biosynthesis [15]. During the trial, the patient’s 
PSA levels increased to 20.9ng/dl (Figure 4H), 
prompting resumption of chemotherapy and G-CSF. This 
time the patient opted to fast prior to chemotherapy.   His  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fasting schedule consisted of 60 hours prior to and 24 
post drug administration (Table 2). Upon restarting 
chemotherapy with fasting the PSA level dropped, and 
notably, the patient reported considerably lower side 
effects than in previous cycles in which he consumed 
calories ad-lib (Figure 4I). He also experienced reduced 
myelosuppression (Figure 4A-G). During the last three 
cycles, in addition to fasting, the patient applied 
testosterone (cream, 1%) for five days prior to 
chemotherapy. As a consequence the PSA level along 
with the testosterone level increased dramatically. 
Nonetheless, 3 cycles of chemotherapy combined with 
fasting reduced PSA from 34.2 to 6.43 ng/ml (Figure 
4H). These results imply that the cytotoxic activity of 
TAX to cancer cells was not blocked by fasting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Laboratory values of blood cell counts for case 4. (A) Neutrophils; (B) Lymphocytes; (C) White blood cells, WBC; (D)
Platelets; (E) Red blood cells, RBC (F) Hemoglobin, Hgb; (G) Hematocrit, Hct;   Filled triangle indicates day of chemotherapy; open square
indicates fasting. Normal ranges of laboratory values are indicated by dash lines; (H) Self‐reported side‐effects after chemotherapy for
case 4. Data represent the average of 5 cycles of chemo‐alone vs 1 cycle of chemo‐fasting treatment. 
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This is a 61-year-old Caucasian female who was 
diagnosed in June 2008 with poorly differentiated non-
small cell lung carcinoma (NSCLC). A staging PET scan 
documented a hypermetabolic lung mass, multiple 
mediastinal and left perihilar lymph nodes, and 
widespread metastatic disease to the bones, liver, spleen, 
and pancreas. The initial treatment commenced with the 
administration of TAX 75 mg/m
2 and CBDCA 540mg 
every 21 days. Although she was on a regular diet, during 
the first 5 cycles she lost an average of 4 pounds after 
each treatment, most likely due to chemotherapy-induced 
anorexia. The patient reported that she did return to her 
original weight but only after three weeks of the drug 
administration, just before a new cycle. Additional side 
effects included severe muscle spasms, peripheral 
neuropathy, significant fatigue, mucositis, easy bruising 
and bowel discomfort (Figure 5H). During the sixth
 
cycle,
 which consisted of the same drugs and dosages, the 
patient fasted for 48-hours-prior and 24-hours-post 
chemotherapy. She lost approximately 6 pounds during 
the fasting period, which she recovered within 10 days 
(data not shown). Besides mild fatigue and weakness, the 
patient did not complain of any other side effect which 
was experienced during the five previous cycles (Figure 
5H). Cumulative side effects such as peripheral 
neuropathy, hair loss and cognitive impairment were not 
reversed. By contrast self-reported acute toxic side 
effects were consistently reduced when chemotherapy 
was administered in association with fasting (Figure 5H). 
In the sixth  and last cycle,   the patient  reported that  her  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
strength returned more quickly after the chemotherapy so 
that she was able to walk 3 miles three days after the drug 
administration, whereas in previous cycles (ad libitum 
diet) she had experienced severe weakness and fatigue 
which limited any physical activity. No significant 
differences were observed in the patient’s blood analysis 
(Figure 5A-G). The last PET scan performed on February 
2009 showed stable disease in the main mass (lungs) and 
decreased uptake in the spleen and liver when compared 
to her baseline study. 
 
Case 5 
 
This is a 74 year-old woman diagnosed in 2008 with 
stage IV uterine papillary serous carcinoma. Surgery 
(Total Abdominal Hysterectomy-Bilateral Salpingo-
Oopherectomy, TAH-BSO, with lymph node 
dissection) followed by adjuvant chemotherapy were 
recommended. Due to significant enlargement of the 
right ureter, a right nephrectomy was also performed. 
Post-operatively, six cycles of CBDCA (480mg) and 
paclitaxel (280mg) were administered every 21-days. 
During the first treatment the patient maintained her 
regular diet and experienced fatigue, weakness, hair 
loss, headache and gastrointestinal discomfort (Figure 
6). By contrast, during cycles 2-6, the patient fasted 
before and after chemotherapy, and reported a reduction 
in the severity of chemotherapy-associated side effects 
(Table 2; Figure 6). Fasting did not appear to interfere 
with chemotherapy efficacy, as indicated by the 87% 
reduction in the tumor marker CA-125 after the forth 
cycle (data not shown).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Self‐reported side‐effects after chemotherapy for case 5. Data represent 1 cycle
of chemotherapy‐alone (first cycle) vs the average of 5 cycles of chemo‐fasting treatments. 
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This is a 44-year-old Caucasian female diagnosed with a 
right ovarian mass (10x12 cm.) in July 2007. Surgery 
(TAH-BSO) revealed stage IA carcinosarcoma of the 
ovary with no lymph node involvement. Adjuvant 
treatment consisted of six cycles of ifosfamide and 
CDDP, administered from July to November of 2007. 
She remained free of disease until an MRI revealed 
multiple new pulmonary nodules in August 2008.  Conse- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quently chemotherapy with taxol, carboplatin and 
bevacizumab was initiated. By November, however, a 
CT scan showed progression of the cancer. Treatment 
was changed to gemcitabine plus TAX complemented 
with G-CSF (Neulasta) (Table 2 and Table S2). After the 
first dose of gemcitabine (900 mg/m
2), the patient 
experienced prolonged neutropenia (Figure 7A) and 
thrombocytopenia (Figure 7D), which forced a delay of 
day 8 dosing. During the second cycle the patient 
received a reduced dose of gemcitabine (720 mg/m
2), but  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Laboratory values of blood cell counts for case 6. (A) Neutrophils; (B) Lymphocytes; (C) White blood cells, WBC; (D)
Platelets; (E) Red blood cells, RBC (F) Hemoglobin, Hgb; (G) Hematocrit, Hct; Filled triangle indicates day of chemotherapy; open square
indicates fasting. Normal ranges of laboratory values are indicated by dash lines. The patient received red blood cell transfusion (3 units)
on day 71 and also received G‐CSF (Neulasta) as indicated.  
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cytopenia, causing dose delays. For the third and 
subsequent cycles, the patient fasted for 62 hours prior to 
and 24 hours after chemotherapy. The patient not only 
did not find hardship on carrying out the fasting but also 
showed a faster recovery of her blood cell counts, 
allowing the completion of the chemotherapy regimen 
(gemcitabine 720mg/m
2 on day 1 plus gemcitabine 
720mg/m
2 and TAX 80mg/m
2 on day 8). During the fifth 
cycle, she fasted under the same regimen and received a 
full dose of gemcitabine (900mg/m
2) and TAX (Table 2 
and S2).  Her complete blood count  showed consistent   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
improvement during the cycles in which chemotherapy 
was combined with fasting. A trend in which nadirs were 
slightly less pronounced and the zeniths were 
considerably higher in ANC, lymphocyte and WBC 
counts was observed (Figure 7A, B, C, respectively; 
Table S2). During the first and second cycle (ad libitum 
diet) gemcitabine alone induced prolonged thrombo-
cytopenia, which took 11 and 12 days to recover, 
respectively (Figure 7D; Table S2) but  following the first 
combined fasting-gemcitabine treatment (third
  and 
subsequent cycles), the duration of thrombocytopenia 
was significantly shorter (Figure 7D; Table S2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Laboratory values of blood cell counts for case 7. (A) Neutrophils; (B) Lymphocytes; (C) White blood cells, WBC; (D)
Platelets; (E) Red blood cells, RBC (F) Hemoglobin, Hgb; (G) Hematocrit, Hct; (H) Prostate specific antigen (PSA) level. Filled triangle
indicates day of chemotherapy; open square indicates fasting, arrow indicates abiraterone administration. Normal ranges of laboratory
values  are  indicate  by  dash  lines.  The  patient  also  received  G‐CSF  (Neulasta)  as  indicated;  (I)  Self‐reported  side‐effects  after
chemotherapy for case 7. Data represent the average of 8 cycles of chemo‐fasting treatments. 
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This is a 66-year-old Caucasian male who was 
diagnosed in July 1998 with prostate adenocarcinoma, 
Gleason score 8. A Prosta Scint study performed in the 
same year displayed positive uptake of the radiotracer in 
the right iliac nodes, consistent with stage D1 disease. 
The patient was treated with leuprolide, bicalutamide 
and finasteride. In December 2000, the diseases 
progressed. He started on a second cycle with leuprolide 
acetate and also received High Dose Rate (HDR) 
brachytherapy and external beam radiation with 
Intensity Modulated Radiation Therapy (IMRT) to the 
prostate and pelvis. In April 2008, a Combidex scan 
revealed a 3 x 5 cm pelvic mass and left hydronephrosis 
prompting initiation of TAX chemotherapy supplement-
ed with G-CSF.  The patient received 60-75 mg/m
2 of 
TAX for 8 cycles. Throughout this period the patient 
fasted for 60-66 prior to and 8-24 hours following 
chemotherapy (Table 2). Side effects from fasting 
included grade one lightheadedness (accordingly CTCAE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0) and a drop in blood pressure, none of which 
interfered with his routine. Chemotherapy-associated 
self-reported side effects included grade one sensory 
neuropathy (Figure 8I). The patient’s ANC, WBC, plate-
let and lymphocyte levels remained in the normal range 
throughout treatment, although he did develop anemia 
(Figure 8A-G). PSA levels consistently decreased, 
suggesting that fasting did not interfere with the 
therapeutic benefit of the chemo-treatment (Figure 8H). 
 
Case 8 
 
This is a 53-year-old Caucasian female who was 
diagnosed with stage IIA breast cancer (HER2+) in 
2008. After a lumpectomy procedure, she received 4 
cycles of adjuvant chemotherapy with TAX (75mg/m
2) 
and CTX (600mg/m
2) every 21 days. For all 4 cycles 
the patient fasted 64 hours prior to and 24 hours post 
chemotherapy administration (Table 2). Self-reported 
side effects included mild weakness and short-term 
memory impairment (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Self‐reported side‐effects after chemotherapy for case 8.
Data represent the average of 4 cycles of chemo‐fasting treatments. 
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This is a 48 year-old Caucasian female diagnosed with 
breast cancer. Her adjuvant chemotherapy consisted of 
4 cycles of doxorubicin (DXR, 110mg/dose) combined 
with CTX (1100mg/dose) followed by weekly 
paclitaxel and trastuzumab for 12 weeks. Prior to her 
first chemotherapy treatment, the patient fasted for 48 
hours and reported no adverse effects. During the 
second and subsequent cycles the patient fasted for 60 
hours prior to the chemotherapy followed by 5 hours 
post drug administration (Table 2). She reported no 
difficulties in completing the fasting. Although she 
experienced alopecia and mild weakness, the patient did 
not suffer from other commonly reported side effects 
associated with these chemotherapy drugs (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 10 
 
This is a 78 year-old Caucasian female diagnosed with 
HER2 positive breast cancer. After mastectomy, six 
cycles of adjuvant chemotherapy were prescribed with 
CBDCA 400 mg (AUC= 6), TAX (75mg/m
2) 
complemented with G-CSF (Neulasta), followed by 6 
months of trastuzumab (Table 2). Throughout the 
treatment the patient fasted prior and after 
chemotherapy administration. Although the patient 
adopted fasting regimens of variable length, no severe 
side effects were reported (Figure 11H; Table 2). Her 
WBC, ANC, platelet and lymphocyte counts remained 
within normal levels (Figure 11A-D) throughout the 
treatment, but she developed anemia (Figure 11E-G). 
 
 
Figure 10. Self‐reported side‐effects after chemotherapy for case 9.
Data represent the average of 4 cycles of chemo‐fasting treatments. 
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DISCUSSION 
 
Dietary recommendations during cancer treatment are 
based on the prevention or reversal of nutrient 
deficiencies to preserve lean body mass and minimize 
nutrition-related side effects, such as decreased appetite, 
nausea, taste changes, or bowel changes [16]. 
Consequently, for cancer patients who have been 
weakened by prior chemotherapy cycles or are 
emaciated, many oncologists could consider a fasting-
based strategy to be potentially harmful.  Nevertheless  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Laboratory values of blood cell counts for case 10. (A) Neutrophils; (B) Lymphocytes; (C) White blood cells, WBC; (D) 
Platelets; (E) Red blood cells, RBC (F) Hemoglobin, Hgb; (G) Hematocrit, Hct. Filled triangle indicates day of chemotherapy; open square
indicates fasting. Normal ranges of laboratory values are indicated by dash lines. The patient also received G‐CSF (Neulasta) as indicated. 
(H) Self‐reported side‐effects after chemotherapy for case 10. Data represent the average of 6 cycles of chemo‐fasting treatments. 
 
 
 
 
studies in cell culture and animal models indicate that 
fasting may actually reduce chemotherapy side effects 
by selectively protecting normal cells [9]. Following the 
publication of this pre-clinical work,  several patients, 
diagnosed with a wide variety of cancers, elected to 
undertake fasting prior to chemotherapy and shared 
their experiences with us. In this heterogeneous group 
of men and women fasting was safely repeated in 
multiple cycles for up to 180 hours prior and/or 
following chemotherapy. Minor complaints that arose 
during fasting included dizziness, hunger, and headaches 
 
 
www.impactaging.com                    15                                   AGING, December 2009, Vol.1 No.12at a level that did not interfere with daily activities. 
Weight lost during fasting was rapidly recovered in most 
of the patients and did not lead to any detectable harm. 
 
We obtained self-reported assessments of toxicity from 
all 10 patients who incorporated fasting with their 
chemotherapy treatments. Since many of the 
chemotoxicities are cumulative, we evaluated serial data 
including all the combined fasting- and non-fasting (ad 
libitum diet) associated chemotherapy cycles (Figure 
S1). Toxicity was graded utilizing a questionnaire based 
on the Common Terminology Criteria for Adverse 
Events of National Cancer Institute, version 3.0 (Table 1).  
Although the lack of prospective collection of toxicity 
data and grading are a significant limitation, this series 
provide an early insight into the feasibility and potential 
benefit of combining fasting with chemotherapy. Fewer 
and less severe chemotherapy-induced toxicity was 
reported by all the patients in combination with fasting, 
even though fasting cycles were often carried out in the 
later portion of the therapy (Figure S1). Nausea, 
vomiting, diarrhea, abdominal cramps, and mucositis 
were virtually absent from the reports of all 10 patients 
in the cycles in which fasting was undertaken prior to 
and/or following chemotherapy; whereas at least one of 
these symptoms was reported by 5 out of the 6 patients 
during cycles in which they ate ad libitum (Figure S1). 
The four patients that fasted throughout their treatments 
reported low severity for the majority of the side effects, 
in contrast to the typical experience of cancer patients 
receiving the same chemotherapy regimens (Figures 8I, 
9, 10, 11H). For the 6 patients who received 
chemotherapy with or without fasting, we compared the 
severity of the self-reported side effects in the 2 closest 
fasting/non-fasting (ad libitum diet) cycles in which the 
patient received the same chemotherapy drugs at the 
same dose. There was a general and substantial 
reduction in the self-reported side effects in 
combination with fasting (Figure 1). Symptoms such as 
fatigue and weakness were reported to be significantly 
reduced (p< 0.001 and p< 0.00193, respectively), 
whereas vomiting and diarrhea were virtually absent in 
combination with fasting (Figure 1). In addition, there 
was no side effect whose average severity was reported 
to be increased during fasting-chemotherapy cycles 
(Figure 1 and Figure S1). 
 
Challenging conditions such as fasting or severe CR 
stimulate organisms to suppress growth and 
reproduction, and divert the energy towards cellular 
maintenance and repair to maximize the chance of 
survival [17, 19]. In simple organisms such as yeast, 
resistance to oxidants and chemotherapy drugs can be 
increased by up to 10-fold in response to fasting/starve-
tion and up to 1,000-fold in those cells lacking 
homologs of Ras, AKT and S6 kinase [9]. Nevertheless, 
such protection and oxidative stress resistance is 
completely reversed by the expression of oncogene-like 
genes [9,18]. In mammals, the mechanism(s) responsib-
le for the protective effect of fasting against 
chemotherapy induced-toxic side effects is not 
completely understood. It may involve reduction in 
anabolic and mitogenic hormones and growth factors 
such as insulin and insuline-like growth factor 1 (IGF-1) 
as well as up-regulation of several stress resistance 
proteins[20-25]. In fact, mice with liver specific IGF-I 
gene-deletion (LID) which have ~80% reduction of 
circulating IGF-I and mice with genetic disruptions in 
the IGF-I receptor (heterozygous knockout IGF-IR +/-) 
or its downstream elements have been shown to be 
more resistant against multiple chemotherapy agents 
and oxidative stress, respectively [26, 27]. Alternatively,  
fasting-dependent DSR may be, in part, mediated by 
cell cycle arrest in normal cells whereas transformed 
cells continue to proliferate, remaining vulnerable to 
anticancer drugs [25, 28].  Although mutations driving 
cancer progression are heterogeneous across tumor 
types, the majority of the oncogenic mutations render 
cancer cells independent of growth signals [28, 29], 
which we hypothesize prevents cancer cells from 
responding to the fasting-induced switch to a protected 
mode [9]. Therefore, DSR would have the potential to 
be applied independently of the cancer type. Although 
this has not been yet demonstrated, the remarkable 
effects of fasting on the down-regulation of a number of 
growth factors and signal transduction pathways 
targeted by anti-cancer drugs, including IGF-I and the 
TOR/S6 kinase pathways, raises the possibility that it 
could enhance the efficacy of cancer treatment drugs 
and may even be as effective as some of them. 
 
In summary, in this small and heterogeneous group of 
cancer patients, fasting was well-tolerated and was 
associated with a self-reported reduction in multiple 
chemotherapy-induced side effects. Although bias could 
affect the estimation of the side effects by the patients, 
the case reports presented here are in agreement with the 
results obtained in animal studies and provide prelimina-
ry data indicating that fasting is feasible, safe and has the 
potential to differentially protect normal and cancer cells 
against chemotherapy in humans. Nevertheless, only a 
clinical trial, such as the randomized controlled clinical 
trial currently carried out at the USC Norris Cancer Cen-
ter, can establish whether fasting protects normal cells 
and increases the therapeutic index of chemotherapies. 
 
METHODS 
 
From April 2008 to August 2009, 10 unrelated patients 
diagnosed with a variety of cancer volunteered to 
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invited these patients to complete a self-assessment 
survey based on the Common Terminology Criteria for 
Adverse Events of The National Cancer Institute 
version 3.0. For the purpose of this study only, we 
developed a questionnaire that contained 16 easy 
identifiable and commonly reported side effects; the 
seriousness of the symptoms was graded from 0 to 4 
with each consecutive number corresponding to no side 
effect/mild/moderate/severe and life threatening. 
Adverse effects were further divided into 3 major 
categories including, general, gastrointestinal and 
central/peripheral nervous system side effects, (Table 1, 
original questionnaire). The survey was delivered to 
patients by mail, e mail or fax and every patient was 
instructed to complete it 7 days after each treatment 
cycle. Explanation and assistance to patient’s concern 
were offered throughout the study. The eligibility 
criterion to participate was subjected to those patients 
that had voluntarily fasted prior and/or post 
chemotherapy. Medical records including basic 
demographical information, diagnosis, treatments, 
imaging studies and laboratory analysis were also 
retrospectively reviewed (Tables 2, 3).  All the 
aforementioned procedures were in compliance with the 
Internal review Board of the University of Southern 
California (USC).  
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 SUPPLEMENTARY MATERIAL 
 
 
  
Figure S1. Self‐reported side‐effects after chemotherapy with or without fasting.
Data  represent  average  of  CTCAE  grade  reported  by  all  the  patients  in  this  study.  18
chemotherapy cycles under ad‐lib diet were compared to 46 chemo‐fasting cycles.  
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Table S1. Summary of case 1 
 
Days  Treatment  Fasting 
(hr) 
                  WBC                         ANC 
Nadir*                 Recovery**   
Zenith 
Nadir*               Recovery**   
Zenith   
Pre   Post      (Days)  cell/uL     (Days)          
cell/uL
(Days)   cell/uL    (Days)         
cell/uL
3 Docetaxel    140       40  15         1700          4               3900  15         561             4             2601 
75mg/m2 + 
Cyclophosphamide 
600mg/m2 
ad lib      -    24 Docetaxel    12         1200          6              4600  12         120             6              3036 
75mg/m2 + 
Cyclophosphamide 
600mg/m2 
ad lib       
- 
45 Docetaxel    12         1500           8             4100  12         216             8              2932 
75mg/m2 + 
Cyclophosphamide 
600mg/m2 
66 Docetaxel    120       24    -              -              -              5200  -             -                 -              3567 
75mg/m2 + 
Cyclophosphamide 
600mg/m2 
* Time (in days) to reach the lowest blood cell count after chemotherapy. 
** Time (in days) to reach normal level of blood cell count from nadir day.               Table S2. Summary of case 6 
 
Days Treatment Fasting 
(hr) 
 
   WBC  ANC  PLT 
     
pre 
 
post 
 
G-
CSF 
Nadir* 
(Days) 
cell/
uL 
Recove
ry** 
(Days) 
Zenith 
cell/ul  
Nadir
* 
(Days) cell/uL 
Recove
ry** 
(Days) 
Zenith 
cell/uL  
Nadir* 
(Days) 
cell/u
L 
Recove
ry** 
(Days) 
Zenith 
cell/uL 
4 Gemcitabine   
(900mg/m
2) 
ad 
Lib 
−  −  7 900  16 9000 7  400 16 7500  10  63 11 203 
25          G-
CSF 
                         
27 Gemcitabine   
(720mg/m
2) 
ad 
Lib 
−  − 5  700  2  9200  5  700 2  8100 9 59  12  177 
32          G-
CSF 
                         
33          G-
CSF 
                         
34          G-
CSF 
                         
36          G-
CSF 
                         
39          G-
CSF 
                         
41          G-
CSF 
                         
42          G-
CSF 
                         
43 Gemcitabine   
(720mg/m
2) 
62 24  − 5  700  5  7800  5  700 5  6400 −   −  
48          G-
CSF 
                         
49          G-
CSF 
                         
50          G-
CSF 
                         
51          G-
CSF 
                         
53 Gemcitabine 
720 mg/m2 
Docetaxel 
(80 mg/m2)  
62 24  −  4 1800 3  11800 4  1300  3  10700  8  27  10  280 
54          G-
CSF 
                         
67 Gemcitabine   
(720mg/m2) 
62 24  −  9 2700 5  21400 9  1600  2  18600  −   −  
76 Gemcitabine 
720 mg/m2 
Docetaxel 
(80 mg/m2)  
62 24  −  −  −     −  −     8  38  6  286 
78          G-
CSF 
                         
91 Gemcitabine   
(900mg/m2) 
62 24  −                           
96          −  6 2300 1  16500 6  1500  1  15300  −  −  −  − 
97          G-
CSF 
                         
98 Gemcitabine 
(900 
mg/m2) 
Docetaxel 
(100 
mg/m2) 
62 24  −  6 2300 1  14600 6  1700  1  12800  7  16  7  250 
99          G-
CSF 
                         
112 Gemcitabine   
(900mg/m2) 
      −                                     
             * Time (in days) to reach the lowest blood cell count after chemotherapy. 
            ** Time (in days) to reach normal level of blood cell count from nadir day. 
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